Literature DB >> 18334062

HIV infection and the pancreas: risk factors and potential management guidelines.

Roberto Manfredi1, Leonardo Calza.   

Abstract

One thousand and eighty-one evaluable HIV-infected patients were assessed for pancreatic abnormalities in a prospective case-control study including the whole follow-up period of each patient (minimum 12 months). The 435 patients (40.2%), who experienced at least one episode of confirmed pancreatic laboratory abnormality had a longer duration of seropositivity, exposure to protease inhibitors, a more frequent immunodeficiency, AIDS, chronic liver and/or biliary disease and hypertriglyceridaemia, while no relation was found with antiretroviral administration, and the duration of type of nucleoside analogues, when compared with the 646 controls. High and prolonged laboratory alterations eventually associated with signs of organ involvement occurred in 166 cases (38.2%), and were related to the administration of didanosine, stavudine, lamivudine, pentamidine, cotrimoxazole or antitubercular/antimycobacterial therapy, cytotoxic chemotherapy, illicit substance or alcohol abuse, opportunistic infections, chronic liver and/or biliary disease, a protease inhibitor-based highly active antiretroviral therapy (HAART) and hypertriglyceridaemia (usually associated with HAART administration). No difference was noticed between the 46 patients with clinical and/or imaging evidence of pancreatic involvement and the 120 asymptomatic subjects. Although recurrences of enzyme alterations involved 69.6% of patients, only in 30.1% of cases did a change of the underlying antiretroviral or antimicrobial therapy become necessary. An acute, uncomplicated pancreatitis occurred in nine of the 46 symptomatic subjects (19.6%). A two to four week gabexate and/or octreotide administration (performed in 79 cases of 166, 47.6%), achieved a significant laboratory, clinical and imaging cure or improvement in 82.3% of cases, with a better success rate of combined (gabexate mesilate plus octreotide) vs. single (gabexate mesilate or ocreotide) therapy. Reduced disease recurrences and a better tolerability of antiretroviral regimens, were also noticed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334062     DOI: 10.1258/ijsa.2007.007076

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  7 in total

Review 1.  Emerging reverse transcriptase inhibitors for HIV-1 infection.

Authors:  Mohammad A Rai; Sam Pannek; Carl J Fichtenbaum
Journal:  Expert Opin Emerg Drugs       Date:  2018-05-10       Impact factor: 4.191

Review 2.  Pancreas and Adverse Drug Reactions: A Literature Review.

Authors:  Konrad Sosnowski; Piotr Nehring; Adam Przybyłkowski
Journal:  Drug Saf       Date:  2022-07-05       Impact factor: 5.228

Review 3.  Acute pancreatitis in HIV/AIDS patients: an issue of concern.

Authors:  Gordana Dragovic
Journal:  Asian Pac J Trop Biomed       Date:  2013-06

4.  Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV.

Authors:  Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal:  AIDS Res Treat       Date:  2012-03-11

5.  HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Authors:  Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal:  Int J Hepatol       Date:  2012-03-11

Review 6.  Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review.

Authors:  Natalia Mejias Oliveira; Felipe Augusto Yamauti Ferreira; Raquel Yumi Yonamine; Ethel Zimberg Chehter
Journal:  Einstein (Sao Paulo)       Date:  2014 Jan-Mar

7.  Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation.

Authors:  Wilhelm P Greffrath; Jesslee M du Plessis; Michelle Viljoen; Marike Cockeran
Journal:  South Afr J HIV Med       Date:  2018-06-26       Impact factor: 2.744

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.